Nixodine-S™ Study Signals a Potential Breakthrough Beyond Nicotine

Patented alternative preserved nicotine-like activity at key satisfaction-related receptors while producing a markedly more favorable in vitro cytotoxicity result than nicotine under the conditions tested.

PHOENIX, Aug. 24, 2026 /PRNewswire/ -- Bonguard Naturals today announced results from a new nonclinical study that could open a new chapter in adult nicotine alternatives to advance tobacco harm reduction. Instead of simply changing the device, flavor or delivery format, Nixodine-S™ is designed to replace nicotine itself with a patented, precisely formulated alternative. In laboratory testing, Nixodine-S preserved nicotine-like activity at key receptors associated with nicotine-related satisfaction and reward pathways while producing similar or better in vitro toxicology results compared with nicotine under volume-equivalent conditions.

The study, "Toxicological and Pharmacodynamic Evaluation of Nixodine-S [(S)-6-Methylnicotine] Relative to (S)-Nicotine," compared pure Nixodine-S with pure nicotine across standardized in vitro tests measuring cell viability, genotoxicity, mutagenicity and activation of three human nicotinic acetylcholine receptor subtypes.

While the study does not yet establish clinical safety, it provides a compelling scientific reason to investigate whether adult-use tobacco harm reduction products can move beyond conventional nicotine without giving up a familiar experience.

"For decades, the industry has innovated around nicotine. We are innovating beyond nicotine," said Rick Avila, CEO and Co-Founder of Bonguard Naturals. "The breakthrough is the possibility of preserving the receptor-level activity adult users associate with satisfaction while changing the underlying molecule and not compromising its toxicological profile. This gives the industry a powerful new direction to advance tobacco harm reduction—and gives us a strong scientific foundation for the next phase of research."

Why This Could Change the Industry

Most modern harm reduction product innovation has focused on how nicotine is packaged and delivered. Vapes, pouches, and device technologies may look different, but the active molecule remains nicotine. Nixodine-S changes that premise. It is a patented, non-tobacco-derived formulation designed to replace nicotine volume for volume in existing manufacturing processes—potentially allowing manufacturers to create a new category of tobacco harm reduction products for adult smokers without rebuilding their production systems from the ground up.

For adult tobacco and nicotine users, the promise is equally straightforward: a product designed around the familiar receptor pathways connected to nicotine satisfaction.For manufacturers, Nixodine-S offers a simple nicotine substitution platform rather than another incremental device or flavor extension. For the broader industry, the study supplies early scientific evidence that the experience associated with nicotine may not have to remain inseparable.

Key findings from the study include:

• Lower cytotoxicity in vitro: Nixodine-S did not induce cytotoxicity in the neutral red uptake assay at volume-equivalent concentrations where nicotine produced full loss of cell viability. Nicotine's measured IC₅₀ was 961.8 µg/mL; Nixodine-S remained non-cytotoxic through the equivalent of 2,000 µg/mL nicotine.
• No evidence of genotoxicity in vitro: Nixodine-S and nicotine both tested negative in the in vitro micronucleus assay under all treatment schedules.
• No evidence of mutagenicity in vitro: Nixodine-S and nicotine both tested negative in the Ames bacterial reverse-mutation assay across five bacterial strains, with and without metabolic activation.
• Nicotine-like activity at two key receptors: Nixodine-S demonstrated comparable, and in this study slightly greater, potency at the α4β2 and α3β4 receptor subtypes implicated in nicotine reward pathways. The study's authors note that these differences were small and not likely statistically significant.
• Substantially lower potency at a dopamine-related receptor: Nicotine was at least 19 times more potent than Nixodine-S at the α6/3β2β3 receptor subtype, a major contributor to phasic dopamine amplification in mesolimbic reward circuits. Because nicotine's activity did not fall below the lowest concentration tested, the study's authors note the true difference in potency could not be precisely determined and may be considerably larger.

Purpose-Built for Commercial Products

Nixodine-S contains 6-methylnicotine, but it is not simply raw 6-methylnicotine placed into a product. It is a controlled, diluted and patented formulation engineered as a volume-for-volume alternative to nicotine in the manufacture of adult vape and oral tobacco-product alternatives. That distinction matters: the formulation is intended to give manufacturers a practical, consistent ingredient that can fit established production processes while supporting a new generation of tobacco harm reduction products for adults who cannot or do not want to quit the use of tobacco and nicotine products.

The researchers emphasize that the findings apply specifically to the tested Nixodine-S formulation—not to neat (S)-6-methylnicotine, 6-MN generally or other commercial nicotine-analogue products that may differ in concentration, chirality, solvents, impurities or additional ingredients.

Earlier acute-toxicity findings showing that neat (S)-6-methylnicotine can be more acutely toxic than nicotine directly informed the concentration used in Nixodine-S. This study evaluated the resulting commercial Nixodine-S formulation at volumes equivalent to nicotine, reflecting how the Nixodine-S concentrate is intended to substitute for nicotine in manufacturing.

"The distinction between a neat chemical and a deliberately formulated commercial concentrate is essential," said Rick Avila, CEO and Co-Founder of Bonguard Naturals,. "These findings show that, under volume-equivalent in vitro testing conditions, Nixodine-S was less cytotoxic than nicotine while maintaining a differentiated receptor-activation profile. The results support continued evaluation of Nixodine-S as a distinct nicotine-analogue formulation."

Designed Around Satisfaction—Without Using Nicotine

Why might Nixodine-S still feel relevant to an adult tobacco and nicotine user? At the α4β2 and α3β4 receptor subtypes, Nixodine-S produced activity broadly comparable to nicotine. These pathways are associated with the reinforcement and satisfaction adult nicotine users recognize—the sense that an adult-use product has registered and delivered the expected effect. At the α6/3β2β3 receptor, however, Nixodine-S acted as a much weaker partial agonist and was substantially less potent than nicotine, revealing a differentiated receptor profile rather than a simple copy of nicotine.

"The industry has spent decades redesigning devices, flavors and delivery systems while leaving the core molecule largely unchanged," Avila said. "Nixodine represents a different approach: innovation in the molecule itself. We believe the future of adult alternatives will be built on transparent science, responsible formulation and a willingness to test every assumption."

Research Program and Study Limitations

The work included receptor-activation testing on cloned human channels in mammalian cells conducted at Charles River Discovery in Cleveland, Ohio. Cytotoxicity, genotoxicity and mutagenicity testing was conducted at McKinney Specialty Labs in Richmond, Virginia using internationally recognized OECD testing frameworks. 

The research was funded by Ready Mix Naturals, LLC. Rick Avila is an owner of Bonguard Naturals and Ready Mix Naturals and holds patents related to 6-MN. Several study authors are employees, owners or independent consultants associated with McKinney Regulatory Science Advisors or McKinney Specialty Labs. The study sponsor, Ready Mix Naturals, LLC, did not play a role in the laboratory testing, statistical analysis or manuscript drafting beyond funding the work and Rick Avila's disclosed contributions to the study conceptualization, resources and manuscript review.

The study supports further evaluation and a distinct receptor-activity profile under the conditions tested.

The complete study is available here: https://doi.org/10.1016/j.toxrep.2026.102330.

About Nixodine-S™

Nixodine-S is a patented, flavorless concentrate containing (S)-6-methylnicotine. It is designed for use as a volume-for-volume alternative to nicotine in the manufacture of vapor and oral products intended for existing adult tobacco or nicotine users. Nixodine-S is chemically distinct from conventional nicotine and is not tobacco-derived. Products containing Nixodine-S are intended only for adults 21 and older and are not smoking-cessation products or health-care treatments.

About Bonguard Naturals

Bonguard Naturals is a science-driven American company developing patented nicotine-alternative technology for responsible adult-use product innovation. Through the Nixodine-S platform, Bonguard combines proprietary chemistry, scalable formulation and manufacturing compatibility with a commitment to transparent testing, adult-only commercialization and continued scientific evaluation. For more information, visit www.bonguardnaturals.com.

Important Notice

Products containing Nixodine-S are intended only for persons 21 or older who currently use tobacco or nicotine-containing products. Keep out of reach of children and animals. They are sold for recreational purposes and are not smoking-cessation products or health-care treatments. Human clinical trials have not been completed. Product claims have not been evaluated or approved by the U.S. Food and Drug Administration or another governmental regulatory body. This release describes non-clinical, formulation-specific findings and does not claim that Nixodine-S is safe, risk-free, non-addictive or proven to reduce human disease risk.

SOURCE Bonguard Naturals